Maxcyte (DI) (MXCT)

 155.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 195.00
  • 52 Week Low: 107.50
  • Currency: UK Pounds
  • Shares Issued: 51.36m
  • Volume: 254,897
  • Market Cap: £79.60m

Regulatory News

Updates on CARMA Platform at Upcoming Meetings 30-Sep-2019 07:00 RNS
Results for the Six Months ended 30 June 2019 18-Sep-2019 07:00 RNS
Notice of Results 14-Aug-2019 07:00 RNS
Trading Update 17-Jul-2019 07:00 RNS
MaxCyte to Host Capital Markets Day Today 11-Jul-2019 07:00 RNS
Second Price Monitoring Extn 05-Jul-2019 16:42 RNS
Price Monitoring Extension 05-Jul-2019 16:36 RNS
Annual Report 19-Jun-2019 07:00 RNS
Appointment of Joint Corporate Broker 12-Jun-2019 07:00 RNS
Second Price Monitoring Extn 08-May-2019 16:41 RNS
Price Monitoring Extension 08-May-2019 16:36 RNS
Phase I Clinical Trial of MCY-M11 Progressed 08-May-2019 07:00 RNS
Final Results for Year Ended 31 December 2018 24-Apr-2019 07:00 RNS
Launch of ExPERTT Instrument Family 08-Apr-2019 07:00 RNS
Notice of Full Year Results 26-Mar-2019 07:00 RNS

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Maxcyte (DI) Market Data

Currency UK Pounds
Share Price 155.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 195.00
52 Week Low 107.50
Volume 254,897
Shares Issued 51.36m
Market Cap £79.60m

Maxcyte (DI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Maxcyte (DI) Dividends

No dividends found

Trades for 28-Feb-2020

Time Volume / Share Price
16:26 1,000 @ 150.85p
15:07 5,000 @ 159.85p
15:42 2,675 @ 150.85p
13:52 250,000 @ 155.00p
11:38 10,000 @ 151.85p

Maxcyte (DI) Key Personnel

CEO Doug Doerfler
CFO Ron Holtz

Top of Page